Research programme: LFA-1 inhibitors - Actinobac BiomedAlternative Names: Leukocyte function antigen-1 (LFA-1) antagonist - Actinobac Biomed; Leukothera
Latest Information Update: 03 Apr 2013
At a glance
- Originator University of Medicine & Dentistry of New Jersey
- Developer Actinobac Biomed
- Class Biological toxins
- Mechanism of Action Lymphocyte function-associated antigen-1 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Haematological malignancies; HIV infections; Psoriasis